Video
Dr. Oh on the Sequencing of New Therapies for Prostate Cancer
Author(s):
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses sequencing of new therapies for castration-resistant prostate cancer (CRPC).
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses sequencing of new therapies for castration-resistant prostate cancer (CRPC).
According to Oh, one of the issues about the sequencing of new therapies for CRPC is the lack of evidence to support when a patient should receive chemotherapy or AR-targeted therapy in relation to other treatments.
An electronic medical records system checked 4000 men who had received chemotherapy or AR-targeted therapy and had a short duration of response in the first-line setting. The focus was on the patients who were primarily resistant to AR-targeted therapy and the outcome based on whether they used chemotherapy or a second AR-targeted therapy in the second-line setting.
